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Successful liver failure management using molecular adsorbents recirculating system during complicated
veno-arterial extracorporeal membrane oxygenation as a bridge to a left ventricular assist device placement
Shigeki Tabata, MD, Nicholas Cavarocchi, MD, Hitoshi Hirose, MD.
From Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Objective

ECMO is a well-established therapy for the
patients with cardiogenic shock.
We present a patient who developed severe
complications while on ECMO.
Case presentation-1

Case presentation-2

The patient also developed liver failure with
peak total bilirubin of 56 mg/dl. The molecular
adsorbents recirculating system (MARS) device
was performed from ECMO day 9 to ECMO day
14. Liver function improved and the value of
total bilirubin decreased to 9.9 mg/dl on ECMO
day 19.

A 49 year old female presented with severe
heart failure and was placed on V-A ECMO
for bridge to decision.

On ECMO day 20, the patient underwent a
Heart Mate II LVAD placement and successful
ECMO wean.

While on ECMO, the patient developed
massive hemoptysis after Swan-Ganz
catheter manipulation. After the
endotracheal tube was clamped and the
patient relied on full ECMO support for 36
hours, the hemoptysis resolved.

During the course of surgical recovery, the
patient had two episodes of sepsis and VAD
pocket infection, which was finally controlled
with antibiotic beads placement into the pocket.

Massive hemoptysis & ET tube clamped

The patient was transferred to an acute
rehabilitation facility on ECMO day 77.

ECMO

ET tube unclamped 36 h after hemoptysis

Total bilirubin improved after MARS

MARS

.

Discussion

Among the many possible hematologic
complications, hemoptysis is often difficult to
control. In our patient, the hemoptysis was not
controllable by conventional treatment, thus the
endotracheal tube was clamped to allow the
entire airway to tamponade using the advantage
of ECMO.

Conclusions

To our knowledge, this is the first report of a
patient on ECMO complicated by massive
hemoptysis and severe acute hepatic failure
successfully managed and bridged to LVAD.
Patients can be successfully transitioned from
ECMO to VAD despite major complications if
these complications are successfully treated.

Liver function is most important risk factors to
determine patient survival. The MARS is a cellfree extracorporeal liver support device which
eliminates albumin-bound substances, such as
bilirubin. Using MARS, the patient recovered
liver function to allow to perform LVAD
placement safely.
Contact information

While these mechanical circulatory support,
control of sepsis isolating the source of infection
was essential for patient survival.

Hitoshi Hirose, MD, Ph D.
genex@nifty.com
Associate Professor of Surgery
Division of Cardiothoracic Surgery
Thomas Jefferson University

